SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ARDX

Ardelyx, Inc. (NASDAQ:ARDX)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$2.99-$0.07 (-2.29%)
 
Market cap
$752M
Insider Score
Health Score
Analyst consensus
Listed since
Jun 19, 2014
Market Cap$751.60M-45.6%
Revenue (ttm)$468.22M+17.6%
Net Income-$55.47M+1.9%
EPS-$0.22+4.2%
Shares Out251.37M
PE Ration/a
Forward PE15.77
Dividendn/a
Ex-Dividend Daten/a
Volume6,200,407
Open$3.03
Previous Close$3.06
Day's Range$2.95 - $3.08
52-Week Range$2.80 - $8.40
Beta0.68
AnalystsBuy
Price Target$13.00(+334.78%)
Earnings DateFeb 18, 2027

About ARDX

Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.

Address
400 Fifth Avenue, Waltham, MA, 02451, US
Market Cap
752 million
Employees
489
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$697.12K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $16.50 (+451.8%)

1 firm rating ARDX in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From ARDX’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-2.29%
5 Days
-3.24%
1 Month
-6.56%
6 Months
-51.06%
1 Year
-45.64%

$ARDX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ARDX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ARDX's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ARDX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ARDX Revenue by Segment or Geography

$127.05MTotal
Product sales, net$125.45M98.74%
Product supply revenue$1.38M1.09%
Licensing revenue$216.00K0.17%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ARDX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ARDX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ARDX

XBIState Street SPDR S&P Biotech ETF$22.81M
IWMiShares Russell 2000 ETF$19.33M
VTIVanguard Morningstar Total Stock Market ETF$17.68M
PBEInvesco Biotechnology & Genome ETF$9.65M
VXFVanguard Extended Market ETF$8.57M
IWOiShares Russell 2000 Growth ETF$6.99M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ARDX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
6.54
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
22
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

PBEInvesco Biotechnology & Genome ETF2.22%
BBPVirtus Biotech ETF0.71%
TSCVThrivent ETF Trust - Small Cap Value ETF0.37%
XBIState Street SPDR S&P Biotech ETF0.23%
ISMDInspire Small/Mid Cap ETF0.18%
ESSCEventide Small Cap ETF0.11%
FSMLFranklin Small Cap Enhanced ETF0.09%
VTWGVanguard Russell 2000 Growth ETF0.05%
IBBQInvesco Nasdaq Biotechnology ETF0.05%
IWOiShares Russell 2000 Growth ETF0.05%
PWSPacer WealthShield ETF0.04%
LABUDirexion Daily S&P Biotech Bull 3X Shares0.04%

Weight is the stock’s share of each fund’s holdings.